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Abstract
Objectives—To systematically evaluate the prodrome to mania in youth.
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Methods—New-onset/worsening symptoms/signs of ≥ moderate severity preceding first mania
were systematically assessed in 52 youth (16.2 ± 2.8 years) with a research diagnosis of bipolar I
disorder (BD-I). Youth and/or caregivers underwent semi-structured interviews, using the Bipolar
Prodrome Symptom Scale–Retrospective.

Author Manuscript

Results—The mania prodrome was reported to start gradually in most youth (88.5%), with either
slow (59.6%) or rapid (28.8%) deterioration, while a rapid-onset-and-deterioration prodrome was
rare (11.5%). The manic prodrome, conservatively defined as requiring ≥ 3 symptoms, lasted 10.3
± 14.4 months [95% confidence interval (CI): 6.3–14.4], being present for ≥ 4 months in 65.4% of
subjects. Among prodromal symptoms reported in ≥ 50% of youth, three were subthreshold manic
in nature (irritability: 61.5%, racing thoughts: 59.6%, increased energy/activity: 50.0%), two were
non-specific (decreased school/work functioning: 65.4%, mood swings/lability: 57.7%), and one
each was depressive (depressed mood: 53.8%) or subthreshold manic/depressive (inattention:
51.9%). A decreasing number of youth had ≥ 1 (84.6%), ≥ 2 (48.1%), or ≥ 3 (26.9%) specific
subthreshold mania symptoms (i.e., elation, grandiosity, decreased need for sleep, racing thoughts,
or hypersexuality), lasting 9.5 ± 14.9 months (95% CI: 5.0–14.0), 3.5 ± 3.5 months (95% CI: 2.0–
4.9), and 3.0 ± 3.2 months (95% CI: 1.0–5.0) for ≥ 1, ≥ 2, or ≥ 3 specific symptoms, respectively.
Conclusions—In youth with BD-I, a relatively lengthy, predominantly slow-onset mania
prodrome appears to be common, including subthreshold manic and depressive psychopathology
symptoms. This suggests that early clinical identification and intervention may be feasible in
bipolar disorder. Identifying biological markers associated with clinical symptoms of impending
mania may help increase chances for early detection and prevention before full mania.
Keywords
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prodrome
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Early recognition and prevention in bipolar disorder (BD), particularly in youth, has gained
considerable interest (1–16). The significant impairment and severity associated with BD
underscores the importance of early identification and intervention (17–19). However, the
concept of an identifiable clinical precursor state consisting of subsyndromal (i.e.,
prodromal) symptoms is still controversial for BD (20, 21). Numerous approaches have
been proposed to identify those at highest risk for developing BD (3). These include
studying offspring of patients with BD, focusing on youth with disorders frequently
comorbid with BD [e.g., attention-deficit hyperactivity disorder (ADHD), disruptive
behavior disorders] or preceding BD (i.e., major depressive disorder), assessing
temperamental traits in patients with full BD, or, more recently, following patients with
mania-like symptoms that are subthreshold to BD (3).
Since family history arguably is the most replicated risk factor for BD, many studies focused
on bipolar offspring and described their psychiatric disorders and symptom constellations
(17–19, 22–33). However, these studies are limited by their cross-sectional nature, often
small samples, lack of systematic assessment of symptoms or consideration of severity or
change in symptoms over time. Moreover, longitudinal studies of youth at familial high-risk
for BD have generally reported low rates of conversion to BD (26–29, 30, 31, 33) and
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largely excluded patients without a first-degree relative with the disorder. Furthermore, a
significant proportion of patients with BD report no clear family history of BD, thus limiting
the generalizability of family high-risk studies. Studies investigating inter-episode
symptoms prior to relapse (34, 35) may also have questionable generalizability, as it is
unclear whether the time course and type of prodromal symptoms are identical with early
signs of initial illness manifestation. While childhood depression and ADHD have been
identified as risk factors or comorbid precursor states for BD, conversion usually occurs
after many years, and most of these youth do not develop BD (36–39). Studies that assessed
premorbid temperament and character traits in youth and adults with BD or their offspring
(40–43) reported prevalent clusters of behavioral disinhibition, mood lability, and
oppositionality (10, 33, 44–46,), but these observations may not necessarily be specific to
BD. To date, relatively few studies have characterized the prodrome to BD in detail (for
review, see 10, 11, 15). These have included studies of adults with BD or of caregivers of
children with BD (47–49), or case series of patients enrolled into a program for people at
risk for psychosis who developed BD (8, 9, 50). Across these studies, the following
characteristics have been identified most frequently prior to a first or relapsing manic
episode: depressed mood, changes in energy level, disturbance in sleep, anger dyscontrol,
argumentativeness, irritability, mood swings/lability, reckless/dangerous behavior,
emotional hypersensitivity, diminished concentration, psychomotor change, social isolation,
deterioration in role functioning, increased anxiety, suicidal ideation or attempts,
cyclothymic-hypersensitive temperament traits and psychotic symptoms. However, some
studies were limited by the lack of a systematic assessment to confirm the BD diagnosis and
all employed non-standardized approaches to obtaining information about the putative
prodromal phase. These assessments of the BD prodrome included the use of unstructured
interviews, chart reviews or mailed surveys, resulting in the reporting of symptom
frequencies without knowledge of individual symptom duration, severity or impact.
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The absence of reliable illness markers and information about the presence and timing of
specific signs and symptoms that precede a first mania has limited the development of early
interventions for high-risk samples of BD offspring who have familial risk and significant
mood symptoms (51–55). Moreover, there is a paucity of data about which person (e.g.,
patient, parent, teacher, peer) is most likely to first notice the prodromal symptoms, which
could inform the most effective psychoeducation strategies. Therefore, as a first step, and to
guide future prospective studies of the bipolar prodrome, this study aimed to retrospectively,
but comprehensively characterize subsyndromal symptoms preceding a first mania in youth
with BD, utilizing the Bipolar Prodrome Symptom Scale-Retrospective (BPSS-R) (56). We
hypothesized that a substantial number of youth would have experienced a prodrome of
sufficient duration and severity with a relevant number of recognizable symptoms that
emerged prior to their first syndromal manic episode allowing sufficient time for early
identification and prevention efforts. We further hypothesized that some prodromal
symptoms would be specific to BD, resembling subthreshold mania.
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Material and methods
Subjects
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Included in this study were 52 youth aged 7–21 years with a diagnosis of bipolar I disorder
(BD-I). Subjects were drawn from 111 patients with a clinical diagnosis of BD-I who
originally participated in the prospective [Second-Generation Antipsychotic Treatment
Indications, Effectiveness and Tolerability in Youth (SATIETY)] study investigating the
effects of newly initiated second-generation antipsychotic treatment in youth with psychotic,
mood, and disruptive behavior disorders (57). The study was performed at inpatient and
outpatient child psychiatric facilities located in a semi-urban, tertiary care psychiatric
teaching hospital and was approved by the local Institutional Review Board. Legal guardians
and patients ≥ 18 years of age gave informed written consent; youngsters aged 9–17 years
gave written assent. In a first report on this sample, we compared the characteristics of
patients with psychotic versus non-psychotic mania, exploring the overlap and differences
between the prodrome to a first mania episode with psychosis and the prodrome to a first
episode of schizophrenia based on retrospective studies in the literature (56).
Procedures
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A semi-structured diagnostic interview was used to verify the chart diagnosis of BD. Most
(n = 34) were administered The Schedule for Affective Disorders and Schizophrenia for
School-Age Children (K-SADS) (58) to be consistent with other ongoing studies at our
center and to facilitate data-sharing if participants had already been assessed as part of the
NIMH-funded “Treatment and Outcome of Early-Onset Bipolar Disorder” study (Principal
Investigator: Vivian Kafantaris, M.D.). The Washington University in St. Louis K-SADS
(WASH-U-K-SADS) (59) interview was implemented for patients recruited later (n = 18),
as it was felt that the anchors were more child-specific. Patients and/or their caregivers were
also questioned directly about the family history of mental illness, including BD-I and
bipolar II disorder (BD-II), and the presence of comorbid disorders. These data were
supplemented by information from charts and primary psychiatric care providers.
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Patients with a confirmed diagnosis of BD-I and/or their caregivers independently
underwent a semi-structured interview with the BPSS-R [(56); available from the first
author upon request]. In brief, the BPSS-R was developed to identify youth or adults at
clinical high-risk for mania. The BPSS-R was developed based on the DSM-IV criteria for
mania and depression and available rating scales for BD and major depressive disorder in
youth and in adults. In addition, the BPSS-R development was informed by a review of
existing literature regarding risk factors and early symptoms of BD (3), published scales and
interviews for the assessment of the psychotic prodrome and character traits, input from
experts in the areas of the schizophrenia prodrome and BD, and open questioning of youth
with BD and their caregivers regarding emerging subthreshold symptoms prior to the onset
of a first syndromal bipolar manic, mixed, and depressive episode.
The BPSS-R systematically assesses the onset pattern, duration, severity and frequency of
39 symptoms and signs newly emerging or worsening during the period before a first major
depressive and/or first manic episode. It includes subthreshold manic, depressive, general
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psychopathology and psychotic symptoms. Prodromal symptom severity was rated on an
ordinal scale, with 0 = absent; 1 = mild (i.e., noticeable but not affecting functioning); 2 =
moderate (i.e., clearly noticeable, may affect functioning somewhat); and 3 = severe (i.e.,
clearly noticeable, clearly affecting functioning). Symptom frequency was rated on an
ordinal scale, with 0 = absent; 1 = infrequent (i.e., less than once a week); 2 = moderately
frequent (i.e., a couple of times a week); 3 = very frequent (i.e., present more than 50% of
the time); and 4 = static lifetime or character trait (which is not considered part of the
dynamic prodrome). In case of clearly delineated, comorbid conditions that preceded the
onset of the prodrome (i.e., symptoms limited to this disorder and without a more
generalized dynamic worsening), only worsened symptoms during the prodromal phase are
to be recorded.
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Whenever possible, the patient and one caregiver were interviewed separately about
prodromal symptoms. To increase reliability of the information, patients < 12 years of age
were not interviewed (n = 4: aged 7, 8, 9, and 11 years), so that the information was based
on caregiver report only. Moreover, patients were only interviewed if they had achieved
sufficient stability, indicated by a Clinical Global Impression–Severity (CGI-S) (60) score of
no more than ‘moderate’. In addition to the CGI-S, patients were also rated on the
Children’s Global Assessment Scale (CGAS) (61). All interviews were conducted in person
by the first author, a board certified child and adolescent psychiatrist, or by medical trainees
at the MD or medical student level who were trained and supervised by the first author. All
diagnoses were made or confirmed by the first author who also rated all patients on the CGIS and CGAS.
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The pattern of prodromal symptom onset and deterioration was evaluated using: (i)
subjective responses to a multiple-choice question and (ii) a priori determined time cutoffs
applied to the collected prodromal symptom data: patients/informants were asked: ‘During
the time between the first noticeable symptoms and the first full-manic/mixed episode, did
your/your child’s symptoms: (a) start gradually and slowly get worse; (b) start fairly
gradually and quickly get worse; or (c) start all of a sudden, i.e., you were fine one day and
sick the next?’. Answers translated into the following categories: a = gradual onset/slow
deterioration; b = gradual onset/rapid deterioration; and c = rapid onset/rapid deterioration.
The beginning of the onset phase was defined as the time at which the first newly prodromal
symptom of at least moderate severity emerged. The beginning of the deterioration phase
was defined as a clearly distinguishable cluster of newly emerging prodromal symptoms
distal from the prodrome onset. We defined gradual onset as ≥ 4 months and rapid onset as
< 4 months. While we recognize that four months is an arbitrary cutoff, we felt that this
classification was conservative, erring on the side of caution, leaving sufficient time to
detect an emerging prodrome, establish contact with appropriate health care services, and
initiate appropriate intervention. Assuming that four weeks would be the minimum duration
to intervene in patients displaying marked clinical deterioration, we defined slow
deterioration as ≥ 4 weeks and rapid deterioration as < 4 weeks. Using these criteria, we
derived in addition to the three predetermined patterns described above (i.e., multiple-choice
responses a–c) a fourth prodromal pattern from the data set, i.e., rapid onset with continuous
deterioration, characterized by emergence of most, if not all, prodromal symptoms < 4
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weeks prior to full mania without relevant additional prodromal symptom additions until the
full-manic episode. Prodrome duration and number of symptoms during the prodrome and at
time of the first manic episode were calculated separately for each of the prodromal
trajectories derived from the subjective and objective elicitation methods. Information about
who noticed the prodromal mania symptoms first was elicited from the patients and/or their
caregivers. Finally, we asked patients and caregivers to rate on a scale from 0–100% how
certain they were that the information that they provided was accurate.
Data analysis

Author Manuscript
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Although data were collected for the prodrome prior to first full depressive and manic
episodes, for the purpose of this report, we focused only on the manic prodrome. We
focused on the mania prodrome, as this phase is the defining period prior to the first
diagnosis of BD where bipolar-specific preventive interventions need to be targeted. To
assure clinical relevance of the prodromal symptoms and following the thresholds for
positive psychotic symptoms used in the schizophrenia prodrome literature (62, 63), only
attenuated symptoms of at least moderate severity were included in the analysis.
Furthermore, to assure a dynamic character of emerging symptoms, we only considered as
part of the prodrome those moderately or more severe symptoms that either emerged newly
or worsened during the time preceding the first manic episode. Thus, we excluded symptoms
that were reported as unchanged, life-long temperamental or character traits as well as
preceding symptoms that were stable and could thus be related to comorbid psychiatric
disorders. Although stable symptoms reported by patients and caregivers could be
interpreted as a potentially useful proxy of background psychopathology against which true
prodromal symptom frequency could be judged, we did not include these ratings due to
concerns about confounding the targeted picture of a dynamic and evolving symptomatic
BD prodrome. With the exception of prodrome duration and symptom prevalence in
subgroup analyses, which were also calculated for patient and caregiver responses
separately, patient-informant aggregates of data were used. Consistent with many studies of
psychiatrically ill children and adolescents (17, 59) patient and parent/caregiver responses
were integrated. In case of conflicting results, the positive response, higher (i.e., more
severe) symptom rating and earlier symptom onset was counted. This method of counting
the present, more severe and earlier rating is based on the assumption that patients and
caregivers are differentially able to recognize either internalizing or externalizing symptoms
better, and that symptoms might be forgotten, rather than invented.

Author Manuscript

We used descriptive statistics for the sample description and frequency and duration of
reported prodromal symptoms. Moreover, we compared the frequency and duration of each
of the prodromal symptoms in the group of patients who had a major depressive episode and
a manic episode as their first illness polarity. For comparisons of categorical variables, chisquare tests (or Fisher’s Exact test when cell size was ≤ 5) were used. For continuous
variables, ANOVAs were used. Drawing on results from a study that identified bipolar
mania symptoms with high specificity for BD-I versus ADHD (i.e., elation, grandiosity,
decreased need for sleep, racing thoughts, or hypersexuality) (64), we also analyzed the
number of patients with at least one, two, or three of these ‘specific’ mania prodromal
symptoms, calculating also the mean mania prodrome duration. In addition to analyses of
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the entire sample, we conducted subgroup analyses of the mania prodrome duration and the
symptom prevalence, exploring the potential influence of five clinically relevant variables:
patient versus guardian report; onset of the first manic episode at < 12 versus ≥ 12-years-old;
first-degree family history of BD-I; comorbid oppositional defiant disorder (ODD)/conduct
disorder (CD); comorbid ADHD. These subgroup analyses were conducted using three
different, increasingly conservative definitions of the prodrome, i.e., requiring only one,
two, or three prodromal symptoms to define the onset of the mania prodrome. Unless
indicated otherwise, data are presented as mean ± standard deviation. Except for duration of
the prodrome, where 95% confidence intervals (CI) were calculated, upper and lower limits
are reported. Data were analyzed using JMP 5.0.1, 1989–2003, SAS Institute Inc.
Significance levels were set at p < 0.05; analyses were two-tailed.

Results
Author Manuscript

Sample characteristics
Eighty interviews were conducted in 28 (53.9%) complete patient–informant pairs, 17
(32.7%) parent/guardians alone, and 7 (13.5%) youth alone, yielding information on 52
youth with BD. Two of the original 54 patients were excluded due to a research diagnosis of
BD-II or bipolar disorder not otherwise specified (BD-NOS). Asking patients and caregivers
to rate on a scale from 0–100% how certain they were that the information that they
provided was accurate yielded the following estimate: 83.4% (95% CI: 77.4–89.9).
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Patients were 16.2 ± 2.8-years-old at the time of the interview and had their first manic
episode at age 13.4 ± 3.3 years (Table 1). The interview was conducted 2.8 ± 2.0 years after
the first manic episode. The mean lag between the first full-manic episode and a community
diagnosis of BD was 1.6 ± 2.0 years. In the 35 youngsters in whom interviews were
conducted, the mean CGI-S score was 3.4 ± 1.5, and the mean CGAS score was 56.8 ± 14.0.
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Using a free-report method to assess prodromal manic symptoms, patients and/or caregivers
reported a mean of 4.6 ± 2.1 symptoms that were noted between the onset of any change in
mental state and behavior and the first manic episode. This increased to 13.1 ± 5.0
symptoms, when answers to the semi-structured interview were added. Family members
most often noticed the changes associated with prodromal onset first (80.8%), followed by
patients themselves (46.1%), school personnel (46.1%), peers (40.4%), and health care
personnel (8.8%) (total exceeds 100% due to simultaneous first recognition by several
people). Altogether, 16 patients (30.7%) used marijuana (n = 10), alcohol (n = 8), or cocaine
(n = 3) prior or during the mania prodrome. Of these, only four subjects (or their caregivers)
reported that the substance use triggered or worsened symptoms occurring as part of the
mania prodrome.
Duration and trajectory of the mania prodrome
In the full sample, the mean duration of the manic prodrome, consisting of at least one
symptom of moderate severity, was 18.8 ± 19.2 (95% CI: 13.4–24.2) months. Using cutoff
points of either at least two or at least three symptoms of at least moderate severity, the
mean duration was 12.6 ± 16.8 (95% CI: 8.0–17.3) and 10.3 ± 14.4 (95% CI: 6.3–14.4)
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months, respectively. Using presence of at least moderately severe prodromal symptoms for
≥ 4 months as a threshold, 38 (73.1%) had at least one prodromal symptom present for at
least four months, and 34 (65.4%) each had at least two or three prodromal symptoms
present for ≥ 4 months. Requiring presence of ‘specific’ mania symptoms as part of the
prodrome (i.e., elation, grandiosity, decreased need for sleep, racing thoughts, or
hypersexuality) (58), at least one, two, or three of these symptoms were present in 84.6%,
48.1%, and 26.9% of youth, with an overall prodrome duration of 9.5 ± 14.9 (95% CI: 5.0–
14.0), 3.5 ± 3.5 (95% CI: 2.0–4.9), and 3.0 ± 3.2 (95% CI: 1.0–5.0) months, respectively.
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Table 2 depicts the duration of the subjectively determined onset and deterioration phases of
the manic prodrome (based on responses to a multiple-choice question detailed above),
including the mean number of symptoms during both prodromal phases and during the first
syndromal manic episode. Using this methodology, the majority of patients (59.6%)
reported a gradual symptom onset with slow deterioration, 28.8% had a gradual onset with
rapid deterioration, and only 11.5% had a rapid symptom onset with rapid deterioration.

Author Manuscript

Figure 1 shows the timing of the objectively determined onset and deterioration phases of
the manic prodrome (based on time cutoffs detailed above), including the mean number of
symptoms during both prodromal phases and during the first syndromal manic episode.
Using this pragmatic methodology, most frequently, symptoms during the prodrome had a
gradual onset (≥ 4 months) with slow deterioration (≥ 1 month) (57.7 %), followed by rapid
onset (< 4 months) with rapid deterioration (< 1 month) (17.3%), gradual onset (≥ 4 months)
with rapid deterioration (< 1 month) (13.5%), and a fourth pattern that had emerged from the
data (which had not been part of the multiple-choice answers), consisting of rapid onset (< 4
months) with continuous deterioration (11.5 %). Comparing the number of symptoms at the
prodromal onset or deterioration phase or during the first full mania, only the number of
prodromal symptoms during the onset phase differed across the four groups, being higher in
patients with rapid prodrome onset with continuous deterioration compared to the other
three groups [F(3,48) = 7.19, p = 0.0004]. This difference remained significant after
adjusting for sex, age, race, and individual comorbidities [F(3,48) = 4.79, p = 0.0069].
Individual symptom characteristics and duration of the mania prodrome

Author Manuscript

Table 3 shows the prevalence rates and percent ranks for symptoms present at any time
during the prodrome and for those present for at least four months. In addition, the mean and
median duration of individual prodromal symptoms is displayed. Among the top 13 ranking
symptoms (present in more than 40% of patients) at any time during the prodrome, five each
were either from the general psychopathology domain (drop in school/work functioning,
mood swings/lability, anger outbursts/tantrums, social isolation, anxiety/nervousness) or the
subthreshold mania domain (irritability/anger, racing thoughts, increased energy/activity,
overtalkativeness, reckless/dangerous behavior), two each were from the overlapping
domain of subthreshold manic or depressive symptoms (inattention/distractibility,
psychomotor agitation) or subthreshold depressive symptom domain (depressed mood,
anhedonia), and one was from the overlapping domain of subthreshold manic, depressive or
psychotic symptoms (difficulty thinking clearly).
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Among the 15 most common prodromal symptoms with a rank of 13 or lower (giving
symptoms that tied the same rank and skipping the next rank) that were present for at least
four months in more than one of five patients, five were subthreshold variants of DSM-IV
criteria for mania (i.e., irritability/anger, racing thoughts, increased energy/activity,
overtalkativeness, reckless/dangerous behavior), five belonged to the general
psychopathology domain (drop in school/work functioning, mood swings/lability, anger
outbursts/tantrums, social isolation, anxiety/nervousness), two were subthreshold depressive
in nature (depressed mood, anhedonia), two were either subthreshold manic or depressive
(.inattention/decreased memory, physical agitation), and one was subthreshold manic,
depressive or psychotic (difficulty thinking or communicating clearly). Prodromal symptom
items with the longest durations were most often subthreshold depressive, with five items
having mean durations of at least nine months (depressed mood, increased appetite/weight
gain, worthlessness/guilt, hypersomnia, anhedonia). Four general psychopathology
symptoms (social isolation, oppositionality, mood swings/lability, decreased school/work
functioning), and two subthreshold mania symptoms (reckless/dangerous behavior,
overtalkativeness) had average durations of nine months or longer. Since the standard
deviations for the duration of individual prodromal symptoms were mostly large, we also
calculated the median durations. Although general psychopathology and subthreshold
depressive symptoms had median durations that were longer than those for subthreshold
mania symptoms, five subthreshold mania symptoms (reckless/dangerous behavior, racing
thoughts, overly cheerful/happy, inattention, risky sexual behavior) lasted for a median
duration of ≥ 4 months (Table 3).
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In exploratory analyses comparing patients with and without a full depressive episode prior
to first mania on the frequency and duration of the 39 assessed symptoms, only racing
thoughts was more frequent (78.9% versus 48.5%, p = 0.042) and risky sexual behaviors
was more prolonged (1.5 ± 3.5 versus 0.1 ± 0.7 months, p = 0.038) during the mania
prodrome in patients whose first polarity had been depression.
Subgroup analyses of mania prodrome duration and symptom characteristics
Of five subgroup analyses (Table 4), only the presence of ODD/CD was associated with a
significantly longer prodrome duration using a minimum of ≥ 2 or ≥ 3 prodromal symptoms.
There was a trend toward longer symptom recognition by caregivers compared to patients in
the 28 complete patient–informant pairs, again, more pronounced in the prodrome
characterized by ≥ 2 or ≥ 3 concurrent symptoms.

Author Manuscript

Comparing the assessed prodromal symptoms across the five selected subgroup variables,
only family history and ODD/CD comorbidity were associated with two symptoms each that
were significantly different from patients without this characteristic: presence of a firstdegree family member with BD-I was associated with a higher prevalence of increased
sexual energy and oppositional defiant behavior in youth; and comorbid ODD/CD was
associated with less feelings of euphoria and more worthlessness (Table 5). By contrast,
informant type, an age of onset < 12 years, and comorbid ADHD were not noted to
significantly influence symptom expression during the mania prodrome
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Our results suggest that many youth undergo a relatively lengthy and mostly non-acute
prodromal symptom phase prior to the development of a first full-manic episode. In the
majority of our sample (88.5%), the development of symptoms preceding a first manic
episode was reported to have developed gradually, and the onset phase (defined as the initial
presentation of prodromal symptoms separated from a period proximal to the first full-manic
episode where either symptoms worsened and/or a cluster of additional prodromal
symptoms occurred) was followed predominantly by a slow (59.6%), rather than rapid
(28.8%) deterioration. By contrast, only a minority (11.5%) reported a rapid onset as well as
deterioration pattern of their manic prodrome. Using four months as a minimum duration for
gradual onset, 71.2% of patients had a gradual prodrome onset. Although these findings are
still preliminary and need validation in larger samples, they suggest that the gradual onset in
a majority of patients lends itself to early illness identification and, possibly, interventions
(3, 6) to target early symptom manifestations. This is highlighted by our second and related
finding, that the mean duration of the manic prodrome, using a conservative threshold of ≥ 3
concurrent symptoms of at least moderate severity, lasted for 10.3 months, and that 65.4%
of patients had a mania prodrome consisting of at least three moderately severe concurrent
symptoms that lasted ≥ 4 months. Although the prodrome duration in patients required to
have at least one, two, or three ‘specific’ mania prodrome symptoms was shorter, the
proportion of patients fulfilling these criteria and the 95% CIs of the prodrome duration
indicate that a sizeable group of patients could be identified and receive early interventions,
even when limiting the early recognition focus to generally accepted more specific
symptoms as part of the mania prodrome. Of note, the prodromal symptom duration was
considerably longer than that described in retrospective studies investigating the prodrome
to a manic relapse (mean across studies: 21–29 days, range: 1–120 days) (35), suggesting
that the mechanisms involved in a first mania episode might differ somewhat from those that
occur in a patients whose brain has already undergone changes associated with mania. The
third finding of this study is that patients and/or caregivers reported a mean of 13 symptoms
for the entire prodromal period when asked structured questions, compared to recalling only
4.6 symptoms upon open questioning, underscoring the need for structured inquiries in
patients with recent-onset mania and their caregivers. The reported symptoms consisted of a
mixture of nonspecific general psychopathology and subthreshold depressive symptoms, as
well as more specific subthreshold manic symptoms. Although drop in school/work
functioning was the most frequently reported symptom and several other non-specific,
general psychopathology symptoms were also reported frequently, seven of the 13 most
common prodromal symptoms, present in at least 40% of the sample, were subsyndromal
versions of DSM-IV mania criteria. Enthusiasm about the potential specificity of prodromal
symptoms may be tempered by the fact that many of the reported subthreshold symptoms,
even those overlapping with DSM-IV mania criteria (e.g., irritability, decreased
concentration, agitation, reckless/dangerous behaviors, difficulty thinking, or
communicating clearly), are relatively nonspecific. Nevertheless, the emergence of
subthreshold accelerated mania symptoms, such as racing thoughts, increased energy/goal
directed behavior and overtalkativeness in 59.6%, 50.0%, and 42.3% of patients,
respectively, suggests that these may serve as more specific markers of emerging bipolarity.
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This finding is consistent with less detailed reports of pre-manic symptomatology (33, 47–
49) and high frequencies of these suprathreshold symptoms in full mania across seven
pediatric BD studies (65). This finding in the initial prodrome to a first mania episode is also
consistent with findings from a recent study that followed patients with BD-NOS
prospectively (66). Assessing the degree and predictors of conversion from BD-NOS to BDI or BD-II, the authors found a sizeable conversion rate 45% after a mean of 58 weeks after
intake. Diagnostic conversion was predicted by a parental history of manic symptoms, but
also by an increased intensity of ‘hypomanic’/subyndromal symptoms (66).

Author Manuscript

While our results suggest that, in a sizeable proportion of subjects, the disease begins
insidiously, with subthreshold expressions of the full symptom complement, we also
identified a number of subthreshold depressive symptoms as part of the manic prodrome.
Although a mania prodrome was only rated in the absence of a syndromal major depressive
disorder, the impending development of mixed mania, mostly reported by patients and not
by informants, may be partly responsible for the seemingly high prevalence of subthreshold
depressive symptoms during a pre-manic prodrome. Nevertheless, depressive symptoms
were also identified as part of a manic prodrome in three previous cohorts (33, 47–49).

Author Manuscript

In our sample, 70.6% did not have a first-degree family member with BD and 51.0% did not
have a first- or second-degree member with BD. Nevertheless, the duration of the prodrome
was predominantly non-acute and rich with symptoms that were impairing, underscored by
the fact that almost two thirds of patients experienced a drop in school functioning. These
findings are of great importance with regard to the potential for early interventions. Thus far,
early intervention studies in BD, focusing on offspring of patients with BD or with mood
disorders other than BD-I or BD-II, have yielded promising, but unclear long-term results
(51–55). In these studies, most of our patients who ultimately developed BD-I would have
been excluded. Therefore, future studies should broaden the focus to also include cohorts of
high-risk individuals defined by clinical subthreshold symptoms. The high conversion rate
in subjects with BD-NOS (66), which can be considered the most symptomatic and proximal
prodrome to BD (67), further supports this research direction.

Author Manuscript

Exploratory subgroup analyses showed that the mania prodrome duration and symptom
frequency mostly similar whether or not the patient or caregiver were interviewed and
whether or not patients had a family history of BD-I, pre- or postpubertal onset of mania, or
comorbid ODD/CD or ADHD. The duration of the manic prodrome was significantly longer
only in patients with comorbid ODD/CD and when requiring at least two or at least three
concurrent symptoms. In the 28 patient–guardian pairs, a trend was observed towards an
earlier recognition of the prodrome by guardians, suggesting that educational campaigns for
early recognition should target adults and youth. The overall symptom frequencies were
mostly not different across subgroups. The only exceptions were a relative underreporting of
hallucinations and anhedonia by patients compared to caregivers; an increased prevalence of
hypersexuality (despite a more than one-year earlier age of onset) and oppositionality in
patients with a first-degree family member with BD; and less euphoria and greater
worthlessness in patients with comorbid ODD/CD. The greater tendency to display
hypersexuality in patients with a strong familial risk for BD could represent a behavioral
endophenotype for pediatric bipolarity (64). However, behavioral and environmental
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influences on childhood sexuality, possibly related to parental BD diagnosis (e.g., greater
risk for overstimulation, lack of supervision, abuse, etc.) can also not be ruled out, pointing
to a need for further research. The finding of relatively lower rates of euphoria and greater
feelings of worthlessness in patients with comorbid ODD/CD is consistent with findings in
patients exhibiting severe mood dysregulation. These patients most often fulfill criteria for
ODD/CD (68, 69) and low self-esteem as well as feelings of worthlessness may also
promote oppositional and conduct behaviors, independent of the underlying or ultimate
mood disorder. Nevertheless, due to the small sample size, the significant results from the
subgroup analyses are only hypothesis-generating and need to be examined further in future
studies.

Author Manuscript

In addition to the prodromal symptom duration and pattern observed in our sample, there
was a relatively short mean duration between first full-manic episode and the diagnosis of
BD, which was 1.6 years. This is in contrast to the mean eight-year lag found in the study by
Lish et al. (47) conducted in adults. The faster recognition in our early-onset BD sample
might be explained by greater illness severity (70–73), by recruitment from a center with
expertise in and active research focusing on the identification and treatment of pediatric
bipolar disorder, or by the availability of caregivers and/or teachers who can bring patients
to clinical attention countering some of the lack of illness insight often observed in patients.
In addition, an increased public and mental health awareness of pediatric BD can also have
played a role.

Author Manuscript

The results from this study clearly need to be interpreted within its limitations. These
include its retrospective nature, modest sample size, enrollment of youth with BD-I with
more severe illness expression and/or psychosis, and lack of a control group that would
serve to determine the sensitivity and specificity of specific symptoms and symptom clusters
for the development of BD. At the same time, this study aimed at characterizing the mania
prodrome in patients with a verified BD-I diagnosis in order to assess if the BD prodrome is
sufficiently symptomatic and lengthy in order to allow for early recognition efforts.
Moreover, the focus on more severely ill youth with BD-I prescribed antipsychotic
medications may strengthen the results, as arguably the more severely ill patients are, the
more are early identification and intervention indicated. A further limitation is the lack of
formal mood assessments at the time of the interview, which does not allow us to directly
rule out that residual mood states could have influenced the recalled information. However,
only youth with a CGI-S score of ≤ moderate were interviewed, the mean CGI-S score was
3.4 (mild–moderate), the CGAS score was 56.8 at the time of the interview, and information
was integrated, taking also the caregiver report into account.

Author Manuscript

Further, although the retrospective assessments do not allow us to exclude the possibility
that in some patients’ symptoms of comorbid disorders frequently observed in BD (72, 74)
may have been misattributed as prodromal symptoms, the presence of subsyndromal,
specific BD symptoms in a sizable proportion of our sample makes this less likely. We also
cannot fully exclude the possibility that in some patients syndromal manic symptoms were
erroneously rated as prodromal. However, this seems also unlikely, as clusters of at ≥ 2 or ≥
3 symptoms were present for 12.6 and 10.3 months, respectively, prior to the full mania, and
only 11.5% of patients were characterized by continuous symptom deterioration. In addition,
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although 65.4% of youngsters reported psychotic symptoms as part of their first full-manic
episode, only one to three patients (2–6%) reported attenuated psychotic symptoms (except
for difficulties communicating clearly, which was not specific enough to reliably represent
thought disorder), which occurred mostly within the last month of the prodrome (56). A
related question that requires further study is if and when some patients may have fulfilled
criteria for hypomania or for BD-NOS (66, 75, 76) and whether BD-NOS represents an
intermediate, late prodromal, phase, between attenuated, early prodromal symptoms and first
syndromal mania, whether it can remit by itself, or whether it can also be a stable,
intermediary outcome in certain patient subgroups. Unfortunately, we did not collect data
about the presence, quality, and timing of hypomania or BD-II to assess the trajectory to
BD-I in our sample. Finally, the possibility of different prodromal trajectories and durations
in specific BD subgroups, suggested by the presence of different onset and deterioration
patterns identified in our cohort, deserve further study. However, at least in the separate
analysis of patients with a psychotic versus non-psychotic first manic episode, the overall
mania prodrome duration was not significantly different (i.e., 1.7 ± 1.8 years with
subsequent psychotic mania versus 1.9 ± 1.5 years without subsequent psychotic mania,
p=0.70), although psychotic symptoms emerged late and relatively proximal to full mania
(56).

Author Manuscript
Author Manuscript

Furthermore, compared to other pediatric BD samples (24, 71–74, 76), we observed a
relatively low ADHD rate of only 32.7%. This may limit generalizability, possibly being
due to a cohort effect in youth selected for second-generation antipsychotic use, as we found
significantly lower rates of ADHD in patients with psychotic versus non-psychotic mania
(14.7 versus 66.7%, p = 0.0001) (56). On the other hand, the frequency of ADHD in this
study is consistent with studies (77, 78) consisting predominantly of adolescents and having
equal sex distribution. By contrast, samples with predominance of male and prepubertal
youth may bias the sample toward higher ADHD rates (24, 71–74, 76), supported by the fact
that male participants in a lithium trial were significantly more likely to have ADHD
(57.4%) than females (8.2%) (74). Finally, due to the lack of prospective data collection, we
were unable to determine the temporal sequence of the development of mania and of
frequently comorbid conditions, such as ADHD and internalizing or externalizing disorders.
While one could consider these antecedent and comorbid conditions as part of a more
broadly defined BD prodrome status (78), we distinguished disorders, which clearly
preceded the emergence of other mania-related symptoms and which remained stable, from
the clinical mania prodrome. Although future research may show that in certain patient
subgroups ADHD-like and externalizing or internalizing disorder related presentations are
biologically not separate from BD, current nosology considers these presentations as often
related but distinct conditions. Additional research, integrating clinical, endophenotypic and
genetic approaches (3, 10, 12, 13, 15, 16, 67), is sorely needed to clarify the underpinnings
of these disorders to help distinguish between true biological unity, syndromal overlap,
taxonometric overlap, or biological separateness of bipolar disorder from conditions that are
currently considered comorbid.
In summary, findings from this study suggest that patients with early-onset BD experience a
prodrome of considerable length, symptomatic richness and severity prior to first mania. The
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advantage of this study is the focus on mania-like symptoms in definite converters with the
benefit of eliminating false positives. Clinicians should pay attention to the emergence and
clustering of attenuated mania-like symptoms as constituting potentially the clinical
prodrome of mania. While these findings need to be replicated through prospective studies,
ideally in large multi-site studies that include and integrate biological markers and
endophenotype related to the bipolar phenotype, this investigation provides strong evidence
that early identification during an emerging mania prodrome is possible in a sizeable number
of patients, setting the stage for targeted prevention efforts in both familial and non-familial
BD. There is a crucial need for the field to find evidence-based ways to enrich potentially
non-specific symptom expressions that may or may not progress to full mania with
additional, either clinical or biological markers that will help increase the predictive power
of clinical high-risk presentations for mania. Before treatment guidelines can be developed
the sensitivity and specificity of specific symptoms and symptom constellations need to be
clarified and the generalizability of these findings to other settings and populations needs to
be established.
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Fig. 1.

Mean duration and number of prodromal symptoms during the mania prodrome onset and
deterioration phase. mo = months.
aDefinition of onset pattern based on pragmatically, a priori defined duration threshold of
four months for gradual versus rapid onset and of four weeks for slow versus rapid
deterioration. The deterioration phase consists of a newly emerging symptom cluster after
prodrome onset but before full mania criteria were met.
bTime zero = mean number of symptoms during the first manic episode.
*F(3,48) = 7.19, p = 0.0004 for number of symptoms during onset phase.

Author Manuscript
Bipolar Disord. Author manuscript; available in PMC 2015 August 01.

Correll et al.

Page 20

Table 1

Author Manuscript

Demographic and illness characteristics of 52 youth with bipolar I disorder
Characteristics

Frequency

Demographic information
Age, years, mean ± SD [range]a

16.2 ± 2.8 [7.9–20.9]

Sex, male/female, n (%)

25 (48.1) / 27 (51.9)

Ethnicity/race, n (%)b
  White

33 (64.7)

  African American

  8 (15.7)

  Hispanic

  4 (7.8)

  Asian

  6 (11.8)

Illness characteristics

Author Manuscript

CGI-S scale scorea,c

3.4 ± 1.5

CGAS score a,c

56.8 ± 14.0

Age at first diagnosis of BD, years, mean ± SD [range]

14.5 ± 2.8 [6.5–18.9]

Age at first manic episode, years, mean ± SD [range]

13.4 ± 3.3 [4.8–18.8]

Lag between mania and BD diagnosis, years, mean ± SD [range]

1.6 ± 2.0 [0–6.1]

BD characteristics, n (%)
  BD with onset of mania before age 12

14 (26.9)

  BD with major depression as the first mood episode

20 (38.5)

  First-degree family history of BDb

15 (29.4)

  First- or second-degree family history of BDb

25 (49.0)

Comorbidities, n (%)

Author Manuscript

  Oppositional defiant disorder

25 (48.1)

  Attention-deficit hyperactivity disorder

17 (32.7)

  Substance use disorders

12 (23.1)

  Anxiety disordersd

10 (19.2)

  Learning disability

  4 (7.7)

No. of prodromal symptoms, mean ± SD [range]
  Self-report

4.6 ± 2.1 [0–11]

  Structured interview

12.5 ± 5.1 [3–22]e

  Combined structured interview plus free self-report symptoms

13.1 ± 5.0 [4–22]

SD = standard deviation; CGI-S = Clinical Global Impressions–Severity; CGAS = Children’s Global Assessment Scale; BD = bipolar disorder.

Author Manuscript

a

At time of interview.

b

Based on 51 patients with information (one patient was adopted).

c

Based on 35 interviewed patients.

d

Generalized anxiety disorder: n = 2, obsessive compulsive disorder: n = 4, anxiety disorder not otherwise specified: n = 2, posttraumatic stress
disorder: n = 2.
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2.8 ± 3.6

20.7 ± 17.5

21.0 ± 20.7

Mean ± SD

−1.0 to 6.7

11.0–30.4

13.4–28.6

95% CI

Total prodrome duration,
months

14.8 ± 4.9

12.5 ± 4.6

13.0 ± 5.3

Mean ± SD

9.7–19.9

9.9–15.0

11.0–15.0

95% CI

Total no. of prodromal
symptoms ≥ moderate severity

20.5 ± 3.0

19.4 ± 4.6

20.4 ± 6.2

Mean ± SD

17.3–23.7

16.8–21.9

18.2–22.7

95% CI

Prodrome duration based on onset of at least one newly emerging prodromal symptom of at least moderate severity.

b

Based on a multiple-choice question. Definition of onset and deterioration pattern based on multiple-choice question with three possible answers (see Methods) where patients/caregivers could take
duration, frequency, and severity of symptoms into account.

a

SD = standard deviation; CI = confidence interval.

6 (11.5)

15 (28.8)

Rapid onset with rapid deterioration

31 (59.6)

Gradual onset with rapid deterioration

n (%)

Gradual onset with slow deterioration

Manic prodrome onset and deterioration
patterna

No. of symptoms at time of first full
mania

Author Manuscript

Prodromal symptom trajectories based on a priori selected multiple-choice question

Author Manuscript
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31 (59.6)
26 (50.0)
22 (42.3)
21 (40.4)
20 (38.5)
18 (34.6)
12 (23.1)
10 (19.2)
3 (5.8)

  Increased energy or goal-directed activity

  Overly talkative

  Reckless or dangerous behavior

  Decreased need for sleep

  Overly cheerful or happy

  Overly self-confident

  Increased sexual energy

  Risky sexual behavior

Bipolar Disord. Author manuscript; available in PMC 2015 August 01.
12 (23.1)
12 (23.1)

  Suspiciousness

  Hallucinatory experiences

28 (53.8)
21 (40.4)
19 (36.5)

  Anhedonia

  Insomnia

21 (40.4)

  Depressed mood

Subsyndromal depressive symptoms

  Difficulty thinking or communicating clearly

Subsyndromal manic or psychotic or depressive symptoms

10 (19.2)

  Strange or unusual (non-grandiose) ideas

Subsyndromal psychotic symptoms

  Grandiose ideas

8 (15.7)

25 (48.1)

  Physically agitated

Subsyndromal manic or psychotic symptoms

27 (51.9)

  Decreased concentration/attention/memory

Subsyndromal manic or depressive symptoms

32 (61.5)

  Racing thoughts

Total
prevalence
n (%)

  Irritability or easily angered

Subsyndromal manic symptoms

Bipolar prodrome symptom/sign (≥ moderate
severity)

17

13

5

13

24

24

29

32

8

6

35

29

24

19

16

13

11

7

3

2

Percent
rank

4.1 ± 4.9

9.2 ± 11.6

12.5 ± 18.8

6.6 ± 12.9

7.6 ± 15.4

2.8 ± 4.8

1.4 ± 1.6

1.9 ± 1.7

4.7 ± 5.7

8.6 ± 13.9

4.8 ± 4.8

4.1 ± 3.8

4.3 ± 6.7

6.8 ± 13.6

5.2 ± 10.8

9.0 ± 10.9

9.1 ± 16.9

6.8 ± 14.0

7.5 ± 12.7

8.0 ±11.7

Duration,
months
Mean ± SD

2.0

5.0

5.0

3.0

2.0

0.7

0.6

1.5

2.0

4.0

4.0

3.0

1.6

4.0

1.5

6.0

3.5

2.5

4.0

3.0

Duration,
months
Median

8 (15.4)

13 (25.0)

18 (34.6)

7 (13.5)

3 (5.8)

3 (5.8)

1 (1.9)

2 (3.8)

10 (19.2)

15 (28.8)

2 (3.8)

5 (9.6)

4 (7.7)

9 (17.3)

7 (13.5)

13 (25.0)

11 (21.1)

11 (21.1)

16 (30.8)

15 (28.8)

Present for ≥
4 months
n (%)

19

10

3

21

29

29

35

32

15

7

32

26

27

16

21

10

13

13

5

7

Percent
rank

Author Manuscript

Reported symptoms and signs emerging during the bipolar mania prodrome

Author Manuscript
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30 (57.7)
25 (48.1)
23 (44.2)
22 (43.1)
19 (36.5)
14 (26.9)
11 (21.1)

  Frequent mood swings/lability

  Anger or losing temper a lot

  Social isolation

  Anxiety or nervousness

  Oppositionality

  Obsessions or compulsions

  Ambivalence

28

22

17

11

10

8

4

1

35

34

33

31

24

23

21

20

7.2 ± 17.6

7.2 ± 9.3

13.1 ± 16.4

7.3 ± 12.7

14.6 ± 19.1

8.4 ± 9.8

9.6 ± 13.3

8.8 ± 10.6

9.3 ± 5.5

2.9 ± 5.1

12.1 ± 12.4

6.4 ± 4.4

8.8 ± 21.1

6.1 ± 4.0

5.7 ± 5.4

11.2 ± 10.1

Duration,
months
Mean ± SD

1.0

5.5

7.0

2.6

7.5

5.0

6.0

4.5

12.0

0.5

5.0

6.5

1.5

5.5

3.0

9.0

Duration,
months
Median

Tied rankings are reported by giving the same rank to two symptoms and skipping the next rank.

34 (65.4)

  Decreased school or work functioning

General psychopathology symptoms

3 (5.8)

  Hypersomnia

8 (15.7)

  Physically slowed down

6 (11.5)

12 (23.1)

  Weight loss or ↓ in appetite

7 (13.5)

13 (25.0)

  Tiredness or lack of energy

  Attempting suicide

16 (30.8)

  Thinking about suicide

  Weight gain or ↑ in appetite

17 (32.7)

Author Manuscript

  Feeling worthless or guilty

Author Manuscript
Percent
rank

3 (5.8)

8 (15.4)

19 (36.5)

9 (17.6)

16 (31.4)

15 (28.8)

18 (35.3)

19 (36.5)

2 (3.8)

1 (1.9)

6 (11.5)

6 (11.5)

4 (7.7)

9 (17.3)

7 (14.0)

12 (23.5)

Present for ≥
4 months
n (%)

29

19

1

16

5

7

3

1

32

35

29

24

27

16

21

12

Percent
rank

Author Manuscript

Total
prevalence
n (%)

Author Manuscript

Bipolar prodrome symptom/sign (≥ moderate
severity)

Correll et al.
Page 24

Bipolar Disord. Author manuscript; available in PMC 2015 August 01.

Author Manuscript

Author Manuscript

Author Manuscript
28

  Guardian

36

  No

38

  No

27

  No

35

  No

19.2 ±20.8

18.0 ±16.3

14.4 ± 15.6

23.6 ±21.8

17.8 ±18.3

21.6 ±22.2

16.0 ±18.2

26.3 ± 20.7

16.7 ±21.3

12.2 ± 14.4

Mean ± SD

12.1–26.3

9.7–26.4

8.2–20.5

14.6–32.6

11.8–23.8

8.8–34.4

9.9–22.2

14.9–37.7

8.4–25.0

6.7–17.8

95% CI

0.84

0.083

0.54

0.085

0.12

p-value

12.5 ±18.0

13.0 ±14.5

7.1 ± 9.4

18.7 ±20.8

11.7 ±15.0

15.4 ±21.4

10.1 ±14.9

19.3 ±20.1

11.5 ±18.9

5.1 ±5.2

Mean ± SD

6.3–18.7

5.6–20.5

3.4–10.8

10.1–27.3

6.8–6.6

3.1–27.7

5.1–15.2

8.2–30.4

4.2–18.8

3.1–7.1

95% CI

≥ 2 prodromal symptoms

0.92

0.011

0.49

0.078

0.097

p-value

9.9 ±15.7

11.3 ± 11.9

5.5 ±5.6

15.6 ±18.9

9.3 ±12.8

13.3 ±18.5

8.8 ±13.2

14.6 ± 17.2

9.9 ±17.6

3.3 ±4.0

Mean ± SD

4.5–15.3

5.2–17.4

3.3–7.7

7.8–23.3

5.1–13.5

2.6–24.0

4.3–13.2

5.1–24.1

3.1–16.8

1.8–4.9

95% CI

≥ 3 prodromal symptoms

0.75

0.011

0.38

0.20

0.067

p-value
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Only complete pairs included in the matched-pair analyses.

Based on 51 patients with information (one patient was adopted).

b

a

SD = standard deviation; CI = confidence interval; BD = bipolar disorder; ODD = oppositional defiant disorder; CD = conduct disorder; ADHD = attention-deficit hyperactivity disorder.

17

  Yes

Comorbid ADHD

25

  Yes

Comorbid ODD/CD

14

  Yes

Onset of mania before age 12

15

  Yes

First-degree family history of BDb

28

N

  Patient

Informant8

Moderator variable

≥ 1 prodromal symptom

Subgroup analyses of the mania prodrome duration according to the number of concurrent symptoms

Author Manuscript
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17
35

No

27

No
Yes

25

38

No
Yes

14

Yes

36

No

-

-

Feeling overly happy

-

-

Increased sexual energy

Attenuated hallucinations

Symptom

51.9

16.0

11.1

40.0

12.9

0.0

%

0.0091

0.047

0.019

p-value

-

-

Feeling worthless

-

-

Oppositional defiant behavior

Anhedonia

Symptom

Based on 51 patients with information (one patient was adopted).

c
None of the prodromal symptoms reached statistical significance (p < 0.05).

b

Only complete pairs included in the paired Mest analyses.

a

BD = bipolar disorder; ODD = oppositional defiant disorder; CD = conduct disorder; ADHD = attention-deficit hyperactivity disorder.

Comorbid ADHDc

Comorbid ODD/CD

Onset of mania before age 12c

15

28

Yes

Guardian

First-degree family history of BDb

28

Patient

Informanta

N

Subgroup

Moderator variable

%

18.5

48.0

27.8

60.0

46.6

21.4

Significant subgroup differences regarding prodromal symptom frequencies preceding a first manic episode

0.024

0.030

0.048

p-value
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